Tag results:

PD-L1

Selective Multi-Kinase Inhibition Sensitizes Mesenchymal Pancreatic Cancer to Immune Checkpoint Blockade by Remodeling the Tumor Microenvironment

[Nature Cancer] Scientists performed a systematic high-throughput combination drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi-kinase inhibitor nintedanib, which targeted KRAS-directed oncogenic signaling in mesenchymal PDAC.

Increased Expression of PD-L1 in Endometrial Cancer Stem-Like Cells Is Regulated by Hypoxia

[Frontiers in Bioscience-Landmark] Using flow cytometry and western blot assays, the authors have demonstrated that programmed cell death ligand 1 expression is higher in endometrial cancer stem-like cell derived from endometrial cancer than in nonstem-like cancer cells.

ICAM-1-Mediated Adhesion Is a Prerequisite for Exosome-Induced T Cell Suppression

[Developmental Cell] Scientists reported that the adhesion molecule intercellular adhesion molecule 1 (ICAM-1) co-localized with programmed death ligand 1 (PD-L1) on the exosomes; both ICAM-1 and PD-L1 were upregulated by interferon-γ.

Therapeutic Efficacy of FASN Inhibition in Preclinical Models of HCC

[Hepatology] The therapeutic efficacy and the molecular pathways targeted by TVB3664, either alone or with tyrosine kinase inhibitors or the checkpoint inhibitor anti-PD-L1 antibody, were assessed in human HCC cell lines and multiple oncogene-driven HCC mouse models.

Constructing a Novel Signature Based on Immune-Related lncRNA to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients

[Reproductive Sciences] Researchers assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins, and the signature.

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment...

[OSE Immunotherapeutics SA] OSE Immunotherapeutics SA announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi®, a combination of neoepitopes, for use after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients.

Popular